Payment overview · 2025
General Payments
$607.49
34 reported records · 13 companies
Healthcare provider profile · identity verified
Michael Allen Carter, MD
Allopathic & Osteopathic Physicians|Family Medicine · ERIN, TN · NPI 1639293871
Verified facts
What the public records show
CMS Open Payments records show Michael Allen Carter, MD received $607.49 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Farxiga, Ozempic, Rexulti, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Caplyta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $269.81 | 44.4% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.37 | 8.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.62 | 7.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.96 | 5.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $35.31 | 5.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.77 | 5.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.23 | 5.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.97 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.12 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.79 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.15 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.80 | 2.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.59 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $607.49 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $226.78 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $162.36 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.37 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.03 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.51 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
144 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
452 | 61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1092 | 199 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1036 | 132 |
| Furosemide | Furosemide | 1020 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 750 | 145 |
| Lisinopril | Lisinopril | 620 | 119 |
| Potassium Chloride | Potassium Chloride | 608 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 117 |
| Sertraline Hcl | Sertraline Hcl | 491 | 68 |
| Eliquis | Apixaban | 452 | 61 |
| Losartan Potassium | Losartan Potassium | 442 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 407 | 78 |
| Metformin Hcl | Metformin Hcl | 388 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 381 | 67 |
| Omeprazole | Omeprazole | 366 | 89 |
| Memantine Hcl | Memantine Hcl | 364 | 49 |
| Gabapentin | Gabapentin | 353 | 79 |
| Carvedilol | Carvedilol | 343 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 341 | 65 |
| Donepezil Hcl | Donepezil Hcl | 327 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 60 |
| Buspirone Hcl | Buspirone Hcl | 306 | 55 |
| Mirtazapine | Mirtazapine | 298 | 55 |
| Trazodone Hcl | Trazodone Hcl | 292 | 49 |
| Famotidine | Famotidine | 284 | 58 |
| Alprazolam | Alprazolam | 282 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 267 | 59 |
| Divalproex Sodium | Divalproex Sodium | 251 | 30 |
| Simvastatin | Simvastatin | 251 | 52 |
| Montelukast Sodium | Montelukast Sodium | 230 | 46 |
| Allopurinol | Allopurinol | 221 | 39 |
| Meloxicam | Meloxicam | 207 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 206 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 181 | 46 |
| Tramadol Hcl | Tramadol Hcl | 171 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 40 |
| Lorazepam | Lorazepam | 162 | 37 |
| Baclofen | Baclofen | 160 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 156 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 151 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 149 | 35 |
| Januvia | Sitagliptin Phosphate | 145 | 22 |
| Linzess | Linaclotide | 144 | 29 |
| Risperidone | Risperidone | 144 | 22 |
| Prednisone | Prednisone | 141 | 92 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 46 |
| Levetiracetam | Levetiracetam | 138 | 24 |
| Lactulose | Lactulose | 137 | 19 |
| Meclizine Hcl | Meclizine Hcl | 126 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 125 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 22 |
| Finasteride | Finasteride | 121 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 119 | 19 |
| Diazepam | Diazepam | 118 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 117 | 17 |
| Valsartan | Valsartan | 116 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 19 |
| Celecoxib | Celecoxib | 110 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 22 |
| Atenolol | Atenolol | 108 | 14 |
| Glimepiride | Glimepiride | 107 | 24 |
| Olanzapine | Olanzapine | 107 | 17 |
| Clonazepam | Clonazepam | 105 | 19 |
| Xarelto | Rivaroxaban | 100 | 11 |
| Alendronate Sodium | Alendronate Sodium | 97 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 16 |
| Spironolactone | Spironolactone | 96 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 74 |
| Ozempic | Semaglutide | 86 | 14 |
| Ezetimibe | Ezetimibe | 85 | 17 |
| Lovastatin | Lovastatin | 85 | 12 |
| Bupropion Xl | Bupropion Hcl | 84 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 19 |
| Ibuprofen | Ibuprofen | 75 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 18 |
| Farxiga | Dapagliflozin Propanediol | 73 | 16 |
| Sucralfate | Sucralfate | 73 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Myrbetriq | Mirabegron | 71 | 11 |
| Torsemide | Torsemide | 69 | 15 |
| Propranolol Hcl | Propranolol Hcl | 67 | suppressed |
| Methocarbamol | Methocarbamol | 65 | 25 |
| Metformin Hcl Er | Metformin Hcl | 64 | 16 |
| Galantamine Hbr | Galantamine Hbr | 63 | suppressed |
| Topiramate | Topiramate | 60 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Rivastigmine | Rivastigmine | 59 | 12 |
| Ondansetron Odt | Ondansetron | 58 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 14 |
| Pregabalin | Pregabalin | 58 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 57 | 12 |
| Levofloxacin | Levofloxacin | 57 | 40 |
| Midodrine Hcl | Midodrine Hcl | 57 | suppressed |
| Nifedipine Er | Nifedipine | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Cefdinir | Cefdinir | 54 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 11 |
| Novolog Flexpen | Insulin Aspart | 54 | 21 |
| Azithromycin | Azithromycin | 53 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Glyburide | Glyburide | 53 | 15 |
| Benazepril Hcl | Benazepril Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 20 |
| Bumetanide | Bumetanide | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 11 |
| Glipizide | Glipizide | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 28 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 12 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Premarin | Estrogens, Conjugated | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 18 |
| Fluconazole | Fluconazole | 27 | 24 |
| Nystatin | Nystatin | 27 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Clotrimazole | Clotrimazole | 26 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 14 |
| Cefuroxime | Cefuroxime Axetil | 25 | 22 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Leflunomide | Leflunomide | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 21 |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Caplyta | Lumateperone Tosylate | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Nyamyc | Nystatin | 18 | suppressed |
| Austedo | Deutetrabenazine | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Exelon | Rivastigmine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Asmanex | Mometasone Furoate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Colchicine | Colchicine | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $607.49 · 34 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, CAPLYTA, Dexcom G6 Transmitter, FARXIGA, MINIMED 780G, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error